Tom Burnell

Tom Burnell is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm. Tom has a wealth of experience across healthcare including diagnostics, pharmaceutical services, laboratory services, dietary supplements, and contract manufacturing industries, with an outstanding track record of leading organizational change and orchestrating turnarounds, accelerating growth for startups, and facilitating post-acquisition integration. He has international business development experience spanning 38 countries on 5 continents, achieved triple-digit EBITDA growth in several businesses, and facilitated 39 M&A transactions, creating over $1 billion in shareholder value. Tom was a former Operating Partner at Ampersand Capital Partners, where he served as CEO and/or Executive Chairman of two Ampersand portfolio companies, and he is currently President and CEO of Interpace Biosciences, Inc., a 1315 Capital II, L.P. portfolio company. Tom has a B.S in Animal Science and an M.S. in Animal Nutrition from the University of Nebraska, and a Ph.D. in Nutrition, with an emphasis in Statistics and Biochemistry, from the University of Kentucky.